

## PE anti-mouse CD154 (CD40L)

**Catalog # /** 1385020 / 100 µg

**Size:** 1385015 / 25 µg

**Clone:** SA047C3

**Isotype:** Rat IgG2a, κ

**Immunogen:** mCD40L-transfectants


**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Workshop Number:** HCDM listed

**Concentration:** 0.2 mg/ml



Enriched BALB/c mouse splenic T cells were stimulated with PMA plus ionomycin for 6 hours and then stained with mouse CD154 (CD40L) (clone SA047C3) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).

## Applications:

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** **ELISA Capture<sup>2</sup>:** The purified MH9A4 antibody is useful as the capture antibody in a human IL-9 sandwich ELISA assay, when used in conjunction with the biotinylated MH9D1 antibody as the detecting antibody.

- Application References:**
1. Dent AL, *et al.* 1990. *Nature* 343:714.
  2. Kelly KA, *et al.* 1993. *Int. Immunol.* 5:331.
  3. Sperling AI, *et al.* 1992. *J. Immunol.* 149:3200.
  4. Sperling AI, *et al.* 1997. *J. Immunol.* 159:86.

**Description:** CD154 has been known a 39 kD TNF superfamily member also known as CD40 ligand, gp39, T-BAM, TRAP, and Ly-62. CD154 is an accessory molecule expressed predominantly on activated CD4<sup>+</sup> lymphocytes that bind CD40. CD154 plays an important role in T-B cell costimulation and Ig class switching.

- Antigen References:**
1. Farber JM. 1997. *J. Leukoc. Biol.* 61(3):246-57.
  2. Bonecchi R, *et al.* 1998. *J. Exp. Med.* 187(1):129-34.
  3. Aota K, *et al.* 2018. *J. Oral. Pathol. Med.* 12756.
  4. Kim B, *et al.* 2018. *Data. Brief.* 18:518-522.
  5. Saahene RO, *et al.* 2018. *Cancer Biother. Radiopharm.* 2450.